跳至主要内容
临床试验/NL-OMON56412
NL-OMON56412尚未招募不适用

PANDA-study - Prenatal And Neonatal Development: An offspring study of severe mental illness - PANDA-study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 125 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
125

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 至 64(—)

入选标准

  • •All pregnant women and their partners:
  • •At least 18 years old
  • •Ability to provide informed consent
  • •Singleton pregnancy
  • •Biological parent of the fetus/neonate
  • •Pregnant women and their partners with at least one (future) parent with SMI:
  • •At least one (future) parent with SMI in the mood-psychosis spectrum
  • •diagnosed before current pregnancy, i.e., schizophrenia, bipolar disorder,
  • •severe MDD (i.e., with high recurrence rate and/or hospitalizations), psychosis
  • •NOS, single psychosis < two years ago (not related to drug use; no postpartum
  • •psychosis after a prior pregnancy)
  • •Born from parents who participated in visit 1 and/or 2 or born from parents
  • •who would have qualified for inclusion in the study (in other words, families
  • •can also only participate in visit 3).

排除标准

  • •All pregnant women:
  • •Contraindication for MRI (including claustrophobia, a cardiac implantable
  • •electronic device, ferromagnetic metal implants, piercing (in some cases),
  • •tattoos (in some cases)) (Ghadimi & Sapra, 2022).
  • •Postpartum psychosis (after a prior pregnancy)
  • •Not willing to be informed about incidental findings following MRI assessment
  • •All pregnant women and their partners:
  • •Substance use disorder (alcohol, drugs), active < six months pre pregnancy as
  • •assessed with R4U or current addiction treatment such as methadone or
  • •buprenorphine
  • •Not willing to be informed about neonate*s incidental findings following MRI
  • •All fetuses/neonates:
  • •Preeclampsia or fetal growth restriction at time of inclusion
  • •Neurological illness or structural brain abnormalities
  • •Suspected congenital anomalies or syndromes known to affect neurodevelopment
  • •Chromosomal abnormalities
  • •Genetic abnormalities known to impact neurodevelopment
  • •Premature birth (< 37 weeks)
  • •Pregnant women and their partners without SMI:
  • •A lifetime diagnosis of SMI in the mood-psychosis spectrum as assessed with
  • •the Structured Clinical Interview for DSM-5 (SCID-5; First, 2014).
  • •An SMI in the mood-psychosis spectrum in their first degree relatives
  • •Use of neurotrophic medication
  • •In all (future) parents, (co)morbidity with other psychiatric diagnoses is not
  • •an exclusion criterion.

研究者

相似试验